6533b854fe1ef96bd12ae0bd

RESEARCH PRODUCT

Tauroursodeoxycholic acid for the treatment of chronic hepatitis: a multicentre dose-response study

Pier Maria BattezzatiGiuseppe MontaltoDario ConteFrancesco ZappalàElisabetta BuscariniOnofrio Giuseppe ManghisiR. StabiliniAnnarosa FloreaniCristina CestariAlberto NotarbartoloAndrea CrosignaniMauro PoddaMaurizio SoresiLuigi BuscariniGiampiero Buongiorno

subject

Hepatitismedicine.medical_specialtyChemotherapyHepatologybusiness.industrymedicine.medical_treatmentTauroursodeoxycholic acidChronic liver diseasemedicine.diseaseGastroenterologyUrsodeoxycholic acidchemistry.chemical_compoundLiver diseaseDose–response relationshipInfectious DiseasesEndocrinologychemistryInternal medicineMedicineLiver functionbusinessmedicine.drug

description

Ursodeoxycholic acid (UDCA) improves the biochemical expression of chronic liver disease. Tauroursodeoxycholic acid (TUDCA) was recently shown to have more favourable metabolic properties. We designed a multicenter, randomized, controlled study, aimed at assessing the efficacy of TUDCA for the treatment of chronic hepatitis. One hundred and fifty-five patients with chronic hepatitis were randomly assigned to receive TUDCA at the daily doses of 250, 500 and 1000 mg, or no treatment for 6 months. Aminotransferase and gamma-glutamyl transpeptidase (GGT) serum levels decreased with each dose of TUDCA compared with controls (P<0.001). The 1000 mg dose was followed by more marked improvement compared with 250 mg (P<0.05). A progressive improvement of alanine aminotransferase (ALT) with time (P<0.05) was found only with the two higher doses. TUDCA improves the biochemical expression of chronic hepatitis and daily doses of at least 500 mg are recommended.

yearjournalcountryeditionlanguage
1998-12-01Hepatology Research
https://doi.org/10.1016/s1386-6346(98)00070-9